People
During to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics
26 April 2021 - - US-based biopharmaceutical company Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) has appointed Matthew During, M.D., Ph.D. to the company's Scientific advisory board, effective April 26, 2021, the company said.

During is a Harvard, MIT and Yale trained neuroscientist. He has served for 9 years as a member of the faculty of Yale as Professor of Neurosurgery, and as a Professor at Thomas Jefferson, Cornell, and Ohio State Universities.

He was a pioneer in the use of viral vectors for neurological disorders, and was the first to carry out gene transfer into the brain of a human child.

Dr. During was the Principal Investigator and the FDA sponsor for two pioneering gene therapy studies on neurodevelopmental and movement disorders and has published over 250 scientific articles, with many in the world's most prestigious journals including Nature, Science, Cell, Nature Medicine, Nature Genetics, the Lancet and Science Translational Medicine.

He was a co-founder of Merlin Pharmaceuticals, Neurologix, Vector Neurosciences, Emrys Bio, Nightstar Therapeutics, and founder of Ovid Therapeutics where he previously served as president, chief scientific officer and chair of the Scientific advisory board.

Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies.

The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreement with Factor Bioscience/Novellus.

Brooklyn's most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit.

Additional studies are either underway or planned in other solid tumor cancer indications.
Login
Username:

Password: